CAR-T细胞治疗用于实体瘤的研究进展  

Research progress of CAR-T cell therapy in solid tumors

作　　者：葛玉凤 韩东晖[1] 吴介恒[2] 杨发[1] 谢品[1] 秦卫军[1] 杨安钢[2] 温伟红[2] GE Yu-Feng;HAN Dong-Hui;WU Jie-Heng;YANG Fa;XIE Pin;QIN Wei-Jun;YANG An-Gang;WEN Wei-Hong(Department of Urology, Xijing Hospital,Fourth Military Medical University;Department of Immunology,Fourth Military Medical University,Xi’an 710032, China)

机构地区：[1]第四军医大学西京医院泌尿外科,陕西西安710032 [2]第四军医大学基础部免疫学教研室,陕西西安710032

出　　处：《转化医学电子杂志》2017年第10期50-55,共6页E-Journal of Translational Medicine

基　　金：国家重点基础研究发展计划(973)(2013CB530500);国家自然科学基金(81372225)

摘　　要：嵌合抗原受体(CAR)修饰的T细胞,即CAR-T细胞治疗策略是一种非常热门的免疫治疗策略,它可特异性识别肿瘤抗原,进而发挥特异性的杀伤作用.因此靶向性好,杀伤力强,并且T细胞的有效活化和增殖不依赖于MHC分子,是一种高效的免疫杀伤策略.目前,CAR-T细胞治疗正在从实验室逐渐走向临床.其在淋巴瘤治疗中效果良好,为血液肿瘤提供了治愈的希望.在实体瘤中,由于肿瘤微环境的复杂性,CAR-T细胞的治疗效果尚不理想,但是近年来在实体瘤方面也取得了不错的进展.本文就CAR-T治疗策略在实体瘤方面的研究进展进行综述.T cells modified by chimeric antigen receptor(CAR)therapy strategy,the CAR-T cell therapy,is a popular immune therapy strategy,which could specifically identify tumor antigens and then play a specific killing effect.It is a highly effective immune killer strategy with accurate targeting,strong lethality,and effective activation and proliferation of T cells is not dependent on MHC molecules.At present,CAR-T cell therapy is gradually used from laboratory to clinic,which provides a cure hope for patients with blood tumor owing to a good treatment in lymphoma.The effect of CAR-T cells is not ideal in solid tumors due to the complexity of the tumor microenvironment,while there has been some good progress in solid tumors in recent years.In this paper,CAR-T treatment strategy in solid tumor research progress will be reviewed.

关 键 词：嵌合抗原受体 CAR-T 免疫治疗 实体瘤 

分 类 号：R730.51[医药卫生—肿瘤]